Molecular Partners Ag (MOLN) Common Equity (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Common Equity of $87413.5 for Q1 2026, down 38.69% year-over-year from $142582.7 in Q1 2025, and down 13.03% quarter-over-quarter from $100511.5 in Q4 2025.
Molecular Partners Ag (MOLN) Common Equity (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Common Equity for 7 consecutive years, with $87413.5 the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 38.69% year-over-year to $87413.5; the TTM figure through Mar 2026 stood at $87413.5 (down 38.69% YoY), while the FY2025 annual figure was $100511.5, down 37.83% from the prior year.
- Common Equity declined to $87413.5 in Q1 2026 per MOLN's latest filing, from $100511.5 in the prior quarter.
- Across five years, Common Equity topped out at $276.1 million in Q2 2022 and bottomed at $87413.5 in Q1 2026.
- Historically, Common Equity has averaged $40.0 million across 5 years, with a median of $198898.0 in 2023.
- Annual changes were most pronounced in 2022 — Common Equity soared 109.8% — and 2025, when it sank 99.93%.
- Molecular Partners Ag's Common Equity stood at $244107.5 in 2022, then fell by 18.52% to $198898.0 in 2023, then fell by 18.71% to $161680.6 in 2024, then slumped by 37.83% to $100511.5 in 2025, then decreased by 13.03% to $87413.5 in 2026.
- Business Quant data shows MOLN's Common Equity at $87413.5 in Q1 2026, $100511.5 in Q4 2025, and $119421.7 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 9.79 Bn |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | 87,413.52 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87,413.52 |
| Dec 31, 2025 | 100,511.47 |
| Sep 30, 2025 | 119,421.71 |
| Jun 30, 2025 | 128,835.99 |
| Mar 31, 2025 | 142,582.73 |
| Dec 31, 2024 | 161,680.59 |
| Sep 30, 2024 | 160,178.57 |
| Jun 30, 2024 | 172.03 Mn |
| Mar 31, 2024 | 193,099.03 |
| Dec 31, 2023 | 198,898.02 |
| Sep 30, 2023 | 222,138.52 |
| Jun 30, 2023 | 229.08 Mn |
| Mar 31, 2023 | 240,194.32 |
| Dec 31, 2022 | 244,107.46 |
| Sep 30, 2022 | 260,349.00 |
| Jun 30, 2022 | 276.05 Mn |
| Mar 31, 2022 | 286,399.57 |
| Dec 31, 2021 | 116,355.15 |
| Sep 30, 2021 | 135,515.98 |
| Dec 31, 2020 | 118,602.01 |